Aegis Capital Starts ATA Inc. (ATAI) at Buy

Aegis Capital analyst Nathan Weinstein initiates coverage on ATA Inc. (NASDAQ: ATAI) with a Buy rating and a price target of $26.00.

The analyst commented, "atai Life Sciences is a clinical stage biotechnology company developing treatments for mental health disorders. atai has established a platform structure, with interests in numerous companies and subsidiaries which are pursuing treatments for a highly diverse set of indications, and leveraging an expansive list of APIs, including both psychedelic and non-psychedelic substances. Key portfolio companies on the atai platform include Perception Neuroscience, developing PCN-101, R-ketamine for treatment resistant depression (TRD), Recognify Life Sciences, advancing RL-007 a GABA/ nicotinic modulator for cognitive impairment associated with schizophrenia
(CIAS), DemeRx, progressing DMX-1002, ibogaine for opioid use disorder (OUD), and GABA Therapeutics, researching GRX-917, a deuterated version of etifoxine, for generalized anxiety disorder (GAD), among multiple others. In addition to its portfolio companies which are held as variable interest entities (VIEs) ranging from 50.1% to 100% ownership, atai also maintains a 19.4% stake in Compass Pathways (CMPS; NR) which is developing COMP360, psilocybin therapy for treatment resistant depression (TRD)."

For an analyst ratings summary and ratings history on ATA Inc. click here. For more ratings news on ATA Inc. click here.

Shares of ATA Inc. closed at $17.50 yesterday.

You May Also Be Interested In

• META to capture largest share of users, SNAP to benefit from ad budget shifts - Canaccord Genuity weighs in on TikTok ban
• TechnipFMC (FTI) PT Raised to $30 at BTIG
• MarineMax (HZO) PT Lowered to $35 at Stifel